Duquesne Family Office LLC Buys Shares of 21,500 IQVIA Holdings Inc. (NYSE:IQV)

Duquesne Family Office LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 21,500 shares of the medical research company’s stock, valued at approximately $4,225,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC purchased a new stake in IQVIA in the 4th quarter valued at $33,000. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA in the fourth quarter valued at about $39,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. raised its stake in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the 4th quarter valued at about $60,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 4.1 %

NYSE:IQV opened at $146.12 on Wednesday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The stock has a market cap of $25.76 billion, a P/E ratio of 19.48, a P/E/G ratio of 1.99 and a beta of 1.34. The stock has a 50-day simple moving average of $165.94 and a 200-day simple moving average of $189.86.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on IQV shares. HSBC downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, Citigroup lowered their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $237.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.